Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEL63: 6MHP vaccine combinations in melanoma
NCT02425306Phase 2Terminated
- Start
- May 2015
- Primary completion
- Aug 2017
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of melanoma helper peptide vaccine in melanoma. Started May 2015; status: terminated.
02
Drugs
melanoma helper peptide vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02425306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02425306.